CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function

Summary

To advance our understanding of the mechanisms of human cardiorenal syndrome with emphasis upon the interaction of diuretic therapy and the renal-angiotensin-aldosterone -system and cGMP pathway. The belief is that the chronic AT1 receptor blockade in subjects with compensated CHF and renal dysfunction will improve renal function with increased sodium excretion, glomerular filtration rate and effective renal plasma flow and renal function reserve as compared to the response of placebo-treated subjects.

Timeline

Start

2012-02

Primary completion

2016-06-29

Completion

2016-06-29

Drugs

Indications